Immune‐mediated hemolytic anemia in children after liver and small bowel transplantation
Piotr Czubkowski, Mike Williams, Seema Bagia, Deirdre Kelly, Girish Gupte – 5 April 2011 – Four children who underwent ABO‐compatible combined liver and small bowel transplantation developed severe immune‐mediated hemolytic anemia. The main management strategies were early and aggressive treatment with steroids, the introduction of rituximab (an anti‐CD20 monoclonal antibody), and the use of plasma exchange together with compatible but minimal blood transfusions. Three of the 4 children developed thrombi in the major vessels.